Drug Origin Transparency Act of 2026

119 HR 8339 IH: Drug Origin Transparency Act of 2026 U.S. House of Representatives 2026-04-16 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 119th CONGRESS 2d Session H. R. 8339 IN THE HOUSE OF REPRESENTATIVES April 16, 2026 Ms. Matsui (for herself, Mr. Crenshaw , Ms. Schrier , and Mrs. Hinson ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting, and for other purposes. 1. Short title This Act may be cited as the Drug Origin Transparency Act of 2026 . 2. Enhanced drug manufacturing amount information reporting (a) In general Section 510(j)(3) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360(j)(3) ) is amended— (1) in subparagraph (A), by adding or (2) after paragraph (1) ; and (2) by adding at the end the following: (C) Each report submitted pursuant to subparagraph (A) with respect to a drug shall— (i) include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as— (I) the identity of the respective suppliers of each active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material used in such manufacture, preparation, propagation, compounding, or processing of the drug; and (II) the respective amounts of such drug that were manufactured, prepared, propagated, compounded, or processed using an active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material from each such identified supplier; and (ii) be submitted more frequently than annually, in accordance with a reporting schedule as may be specified by the Secretary in such regulation or guidance, but not more frequently than 4 times per year. (D) Any additional information specified in regulation or guidance pursuant to subparagraph (C) shall be a required element of reports under this paragraph not earlier than 6 months after the date on which such regulation or guidance is issued in final form (and in no event shall the absence of any regulation or guidance issued under subparagraph (C) affect the requirement to report as described in subparagraph (A)). . (b) Conforming amendment Section 510(j)(3)(B) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 510(j)(3)(B) ) is amended by striking subparagraph (A) and inserting this paragraph . 3. Require drug labeling to include original manufacturer and supply chain information Section 502 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 352 ) is amended— (1) in paragraph (b)— (A) by striking (b) If in a package and inserting (b)(1) If in a package ; (B) by striking a label containing (1) the name and place and inserting a label containing— (A) the name and place ; (C) by striking or distributor; and (2) an accurate statement and inserting or distributor; and (B) an accurate statement ; (D) by striking under clause (2) of this paragraph and inserting under this clause ; and (E) by inserting at the end the following: (2) (A) Subject to clause (C), if it is a drug, including an active pharmaceutical ingredient, unless it bears a label containing the name and place of business, and unique facility identifier of the original manufacturer of such drug or active pharmaceutical ingredient, except that the Secretary may provide, by regulation, for reasonable variations in the implementation of such labeling requirements. (B) Subject to clause (C), if it is a drug that is an active pharmaceutical ingredient, unless any accompanying certificate of analysis contains the name and place of business, and unique facility identifier of the original manufacturer of the active pharmaceutical ingredient. (C) The Secretary may provide, by regulation, for reasonable variations in the implementation of labeling requirements specified in this subparagraph. ; and (2) by inserting after paragraph (c) the following: (d) (1) Subject to subparagraph (2), if it is a drug, including an active pharmaceutical ingredient, unless it bears labeling containing the name and place of business of— (A) the original manufacturer of each active pharmaceutical ingredient; (B) each manufacturer, if different from the original manufacturer; and (C) the packer or distributor, if any. (2) The Secretary may provide, by regulation, for reasonable variations or an alternative placement for the labeling requirements specified in subparagraph (1), including by electronic means. .